Published in J Clin Invest on March 01, 2014
Angiotensin converting enzyme enhances the oxidative response and bactericidal activity of neutrophils. Blood (2017) 1.39
Vascular contributions to cognitive impairment and dementia including Alzheimer's disease. Alzheimers Dement (2014) 1.33
Amyloid-clearing proteins and their epigenetic regulation as a therapeutic target in Alzheimer's disease. Front Aging Neurosci (2014) 0.94
New therapeutic approaches for Alzheimer's disease and cerebral amyloid angiopathy. Front Aging Neurosci (2014) 0.89
Therapeutic effects of glatiramer acetate and grafted CD115⁺ monocytes in a mouse model of Alzheimer's disease. Brain (2015) 0.87
Iron increases APP translation and amyloid-beta production in the retina. Exp Eye Res (2014) 0.81
Clearance of cerebral Aβ in Alzheimer's disease: reassessing the role of microglia and monocytes. Cell Mol Life Sci (2017) 0.79
Overexpression of angiotensin-converting enzyme in myelomonocytic cells enhances the immune response. F1000Res (2016) 0.76
Angiotensin-converting enzyme overexpression in myelocytes enhances the immune response. Biol Chem (2014) 0.75
Inhibition of ACE Retards Tau Hyperphosphorylation and Signs of Neuronal Degeneration in Aged Rats Subjected to Chronic Mild Stress. Biomed Res Int (2015) 0.75
ACE overexpression in myelomonocytic cells: effect on a mouse model of Alzheimer's disease. Curr Hypertens Rep (2014) 0.75
The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science (2002) 49.51
Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med (2008) 17.09
Inflammation and Alzheimer's disease. Neurobiol Aging (2000) 12.56
Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science (2010) 8.04
Bone marrow-derived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron (2006) 6.38
Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med (2006) 6.15
Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet (2003) 5.92
Ccr2 deficiency impairs microglial accumulation and accelerates progression of Alzheimer-like disease. Nat Med (2007) 5.87
Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res (2008) 5.29
Inflammation in neurodegenerative disease--a double-edged sword. Neuron (2002) 4.95
Co-expression of multiple transgenes in mouse CNS: a comparison of strategies. Biomol Eng (2001) 4.64
National estimates of the prevalence of Alzheimer's disease in the United States. Alzheimers Dement (2011) 3.42
Microglial cells internalize aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor. Neuron (1996) 3.14
Heterogeneity of CNS myeloid cells and their roles in neurodegeneration. Nat Neurosci (2011) 3.06
Characterization of amyloid deposition in the APPswe/PS1dE9 mouse model of Alzheimer disease. Neurobiol Dis (2006) 2.96
Normal and abnormal biology of the beta-amyloid precursor protein. Annu Rev Neurosci (1994) 2.81
Targeting amyloid-beta peptide (Abeta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in Abeta precursor protein (APP) transgenic mice. J Biol Chem (2005) 2.47
Inflammation, microglia, and Alzheimer's disease. Neurobiol Dis (2009) 2.44
Bone-marrow-derived cells contribute to the recruitment of microglial cells in response to beta-amyloid deposition in APP/PS1 double transgenic Alzheimer mice. Neurobiol Dis (2005) 2.16
β-Adrenergic receptor antagonism prevents anxiety-like behavior and microglial reactivity induced by repeated social defeat. J Neurosci (2011) 2.15
Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid beta-protein. J Alzheimers Dis (2001) 2.02
Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1. Proc Natl Acad Sci U S A (2006) 1.92
Powerful beneficial effects of macrophage colony-stimulating factor on beta-amyloid deposition and cognitive impairment in Alzheimer's disease. Brain (2009) 1.84
Impaired spatial learning in the APPSwe + PSEN1DeltaE9 bigenic mouse model of Alzheimer's disease. Genes Brain Behav (2007) 1.72
Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme. FEBS Lett (2002) 1.68
Identification of amyloid plaques in retinas from Alzheimer's patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. Neuroimage (2010) 1.59
Local neuroinflammation and the progression of Alzheimer's disease. J Neurovirol (2002) 1.59
The microglial phagocytic role with specific plaque types in the Alzheimer disease brain. Neurobiol Aging (2004) 1.56
IFN-gamma promotes complement expression and attenuates amyloid plaque deposition in amyloid beta precursor protein transgenic mice. J Immunol (2010) 1.55
Resident and infiltrating central nervous system APCs regulate the emergence and resolution of experimental autoimmune encephalomyelitis. J Immunol (2001) 1.53
Systemic inflammatory cells fight off neurodegenerative disease. Nat Rev Neurol (2010) 1.52
Proteolytic processing of Alzheimer's β-amyloid precursor protein. J Neurochem (2011) 1.50
Prolonged microglial cell activation and lymphocyte infiltration following experimental herpes encephalitis. J Immunol (2008) 1.48
Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. J Biol Chem (2005) 1.44
Trafficking CD11b-positive blood cells deliver therapeutic genes to the brain of amyloid-depositing transgenic mice. J Neurosci (2010) 1.42
Transgenic mice demonstrate a testis-specific promoter for angiotensin-converting enzyme. J Biol Chem (1991) 1.37
A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme. Pharmacol Rev (2012) 1.31
Mice with enhanced macrophage angiotensin-converting enzyme are resistant to melanoma. Am J Pathol (2007) 1.30
Large meta-analysis establishes the ACE insertion-deletion polymorphism as a marker of Alzheimer's disease. Am J Epidemiol (2005) 1.28
Phagocytosis of amyloid-beta and inflammation: two faces of innate immunity in Alzheimer's disease. J Alzheimers Dis (2007) 1.28
Angiotensins in Alzheimer's disease - friend or foe? Trends Neurosci (2009) 1.25
Selective ablation of bone marrow-derived dendritic cells increases amyloid plaques in a mouse Alzheimer's disease model. Eur J Neurosci (2007) 1.24
Cell mediators of inflammation in the Alzheimer disease brain. Alzheimer Dis Assoc Disord (2000) 1.22
Mice lacking endothelial angiotensin-converting enzyme have a normal blood pressure. Circ Res (2002) 1.19
Complement component C1q modulates the phagocytosis of Abeta by microglia. Exp Neurol (2000) 1.19
Angiotensin-converting enzyme converts amyloid beta-protein 1-42 (Abeta(1-42)) to Abeta(1-40), and its inhibition enhances brain Abeta deposition. J Neurosci (2007) 1.17
Neuroprotective properties of the innate immune system and bone marrow stem cells in Alzheimer's disease. Mol Psychiatry (2006) 1.16
Angiotensin-converting enzyme (ACE) levels and activity in Alzheimer's disease, and relationship of perivascular ACE-1 to cerebral amyloid angiopathy. Neuropathol Appl Neurobiol (2007) 1.14
Effects of prolonged angiotensin-converting enzyme inhibitor treatment on amyloid beta-protein metabolism in mouse models of Alzheimer disease. Neurobiol Dis (2007) 1.13
Role of the N-terminal catalytic domain of angiotensin-converting enzyme investigated by targeted inactivation in mice. J Biol Chem (2004) 1.13
Spatial learning and memory impairment and increased locomotion in a transgenic amyloid precursor protein mouse model of Alzheimer's disease. Behav Brain Res (2011) 1.12
The ACE gene and Alzheimer's disease susceptibility. J Med Genet (2000) 1.11
Reducing cerebral microvascular amyloid-beta protein deposition diminishes regional neuroinflammation in vasculotropic mutant amyloid precursor protein transgenic mice. J Neurosci (2005) 1.07
Visuo-spatial learning and memory deficits on the Barnes maze in the 16-month-old APPswe/PS1dE9 mouse model of Alzheimer's disease. Behav Brain Res (2009) 1.06
The renin-angiotensin system and antihypertensive drugs in Alzheimer's disease: current standing of the angiotensin hypothesis? J Alzheimers Dis (2012) 1.05
Alzheimer's disease as proteolytic disorders: anabolism and catabolism of beta-amyloid. Neurobiol Aging (1998) 1.05
The carboxypeptidase ACE shapes the MHC class I peptide repertoire. Nat Immunol (2011) 1.04
Mechanisms of mononuclear phagocyte recruitment in Alzheimer's disease. CNS Neurol Disord Drug Targets (2010) 1.03
Attenuation of AD-like neuropathology by harnessing peripheral immune cells: local elevation of IL-10 and MMP-9. J Neurochem (2009) 1.02
Neuroinflammation and Alzheimer's disease: critical roles for cytokine/Abeta-induced glial activation, NF-kappaB, and apolipoprotein E. Neurobiol Aging (2000) 1.01
Microglial contribution to oxidative stress in Alzheimer's disease. Ann N Y Acad Sci (2000) 0.96
Abeta42-to-Abeta40- and angiotensin-converting activities in different domains of angiotensin-converting enzyme. J Biol Chem (2009) 0.96
ACE I/D polymorphism is a risk factor of Alzheimer's disease but not of vascular dementia. Neurosci Lett (2004) 0.93
Clearance of amyloid-β peptides by microglia and macrophages: the issue of what, when and where. Future Neurol (2012) 0.93
Quantification of the A beta peptide in Alzheimer's plaques by laser dissection microscopy combined with mass spectrometry. J Mass Spectrom (2005) 0.92
The biphasic role of microglia in Alzheimer's disease. Int J Alzheimers Dis (2012) 0.91
Control of murine Ly6C(high) monocyte traffic and immunosuppressive activities by atypical chemokine receptor D6. Blood (2012) 0.90
Targeting beta-amyloid pathology in Alzheimer's disease with Abeta immunotherapy. Neurotherapeutics (2008) 0.90
Angiotensins and Alzheimer's disease: a bench to bedside overview. Alzheimers Res Ther (2009) 0.88
The angiotensin 1-converting enzyme insertion (I)/deletion (D) polymorphism does not influence the extent of amyloid or tau pathology in patients with sporadic Alzheimer's disease. Neurosci Lett (2002) 0.88
Common variants of ACE contribute to variable age-at-onset of Alzheimer's disease. Hum Genet (2004) 0.87
Angiotensin-converting enzyme overexpression in mouse myelomonocytic cells augments resistance to Listeria and methicillin-resistant Staphylococcus aureus. J Biol Chem (2010) 0.87
Nontraditional roles of angiotensin-converting enzyme. Hypertension (2012) 0.86
Beta-amyloid production, aggregation, and clearance as targets for therapy in Alzheimer's disease. Cell Mol Neurobiol (2002) 0.86
Catabolic attacks of membrane-bound angiotensin-converting enzyme on the N-terminal part of species-specific amyloid-beta peptides. Eur J Pharmacol (2008) 0.86
Egr1 expression is induced following glatiramer acetate immunotherapy in rodent models of glaucoma and Alzheimer's disease. Invest Ophthalmol Vis Sci (2011) 0.82
Inhibition of converting enzyme in brain tissue and cerebrospinal fluid of rats following chronic oral treatment with the converting enzyme inhibitors ramipril and Hoe 288. J Cardiovasc Pharmacol (1989) 0.82
Developmental exposure to corticosterone: behavioral changes and differential effects on leukemia inhibitory factor (LIF) and corticotropin-releasing hormone (CRH) gene expression in the mouse. Psychopharmacology (Berl) (2006) 0.79
Recent approaches targeting beta-amyloid for therapeutic intervention of Alzheimer's disease. Recent Pat CNS Drug Discov (2011) 0.79
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer (2006) 8.50
Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail (2013) 4.98
Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene (2004) 4.29
Uncoupled cardiac nitric oxide synthase mediates diastolic dysfunction. Circulation (2010) 2.95
Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res (2004) 2.89
The absence of intrarenal ACE protects against hypertension. J Clin Invest (2013) 2.31
Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res (2008) 2.12
Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). Oncogene (2005) 2.06
Inhibition of brain tumor growth by intravenous poly (β-L-malic acid) nanobioconjugate with pH-dependent drug release [corrected]. Proc Natl Acad Sci U S A (2010) 2.05
Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1. Proc Natl Acad Sci U S A (2006) 1.92
The use of interleukin 12-secreting neural stem cells for the treatment of intracranial glioma. Cancer Res (2002) 1.85
Molecular testing in the management of cardiac transplant recipients: initial clinical experience. J Heart Lung Transplant (2006) 1.84
Inhibition of c-Src tyrosine kinase prevents angiotensin II-mediated connexin-43 remodeling and sudden cardiac death. J Am Coll Cardiol (2011) 1.80
Micropuncture determination of nephron function in mice without tissue angiotensin-converting enzyme. Am J Physiol Renal Physiol (2004) 1.73
Induction of glioblastoma apoptosis using neural stem cell-mediated delivery of tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res (2002) 1.72
Cardiac specific increase in aldosterone production induces coronary dysfunction in aldosterone synthase-transgenic mice. Circulation (2004) 1.67
ACE and ACE2 activity in diabetic mice. Diabetes (2006) 1.66
Mice with cardiac-restricted angiotensin-converting enzyme (ACE) have atrial enlargement, cardiac arrhythmia, and sudden death. Am J Pathol (2004) 1.64
Identification of amyloid plaques in retinas from Alzheimer's patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. Neuroimage (2010) 1.59
DC isoketal-modified proteins activate T cells and promote hypertension. J Clin Invest (2014) 1.59
Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res (2004) 1.57
Glioma tropic neural stem cells consist of astrocytic precursors and their migratory capacity is mediated by CXCR4. Neoplasia (2004) 1.56
Immune activation caused by vascular oxidation promotes fibrosis and hypertension. J Clin Invest (2015) 1.55
Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother (2012) 1.54
High-resolution genomic copy number profiling of glioblastoma multiforme by single nucleotide polymorphism DNA microarray. Mol Cancer Res (2009) 1.53
Spheres isolated from 9L gliosarcoma rat cell line possess chemoresistant and aggressive cancer stem-like cells. Stem Cells (2007) 1.53
Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo. Clin Cancer Res (2007) 1.53
Polycefin, a new prototype of a multifunctional nanoconjugate based on poly(beta-L-malic acid) for drug delivery. Bioconjug Chem (2006) 1.51
Generation of neural progenitor cells from whole adult bone marrow. Exp Neurol (2002) 1.49
Antigen-specific T-cell response from dendritic cell vaccination using cancer stem-like cell-associated antigens. Stem Cells (2009) 1.47
Regulation of steady-state beta-amyloid levels in the brain by neprilysin and endothelin-converting enzyme but not angiotensin-converting enzyme. J Biol Chem (2006) 1.42
Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells. Cancer Res (2006) 1.42
Evolution of late-life mortality in Drosophila melanogaster. Evolution (2002) 1.41
Diagnosis of meningioma by time-resolved fluorescence spectroscopy. J Biomed Opt (2006) 1.36
A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme. Pharmacol Rev (2012) 1.31
Mice with enhanced macrophage angiotensin-converting enzyme are resistant to melanoma. Am J Pathol (2007) 1.30
Infratentorial supracerebellar resection of a pineal tumor using a high definition video exoscope (VITOM®). J Clin Neurosci (2011) 1.27
HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells. Cancer Res (2004) 1.26
Lysine-specific molecular tweezers are broad-spectrum inhibitors of assembly and toxicity of amyloid proteins. J Am Chem Soc (2011) 1.25
Selective ablation of bone marrow-derived dendritic cells increases amyloid plaques in a mouse Alzheimer's disease model. Eur J Neurosci (2007) 1.24
Gain-of-function mutant of angiotensin II receptor, type 1A, causes hypertension and cardiovascular fibrosis in mice. J Clin Invest (2007) 1.23
Is angiotensin II a direct mediator of left ventricular hypertrophy? Time for another look. Hypertension (2007) 1.22
Nanoconjugate based on polymalic acid for tumor targeting. Chem Biol Interact (2007) 1.22
Fluorescence lifetime spectroscopy of glioblastoma multiforme. Photochem Photobiol (2004) 1.20
Interleukin-23-expressing bone marrow-derived neural stem-like cells exhibit antitumor activity against intracranial glioma. Cancer Res (2006) 1.19
Mice lacking endothelial angiotensin-converting enzyme have a normal blood pressure. Circ Res (2002) 1.19
Association between laminin-8 and glial tumor grade, recurrence, and patient survival. Cancer (2004) 1.18
Effect of reduced angiotensin-converting enzyme gene expression and angiotensin-converting enzyme inhibition on angiotensin and bradykinin peptide levels in mice. Hypertension (2004) 1.17
Induction of a CD4+ T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma. J Immunol (2004) 1.17
Polymalic acid-based nanobiopolymer provides efficient systemic breast cancer treatment by inhibiting both HER2/neu receptor synthesis and activity. Cancer Res (2011) 1.16
Inhibition of laminin-8 in vivo using a novel poly(malic acid)-based carrier reduces glioma angiogenesis. Angiogenesis (2006) 1.15
Cardiac-restricted angiotensin-converting enzyme overexpression causes conduction defects and connexin dysregulation. Am J Physiol Heart Circ Physiol (2007) 1.15
Multimodal wide-field two-photon excitation imaging: characterization of the technique for in vivo applications. Biomed Opt Express (2011) 1.13
Role of the N-terminal catalytic domain of angiotensin-converting enzyme investigated by targeted inactivation in mice. J Biol Chem (2004) 1.13
Temozolomide delivery to tumor cells by a multifunctional nano vehicle based on poly(β-L-malic acid). Pharm Res (2010) 1.13
Intrarenal angiotensin-converting enzyme induces hypertension in response to angiotensin I infusion. J Am Soc Nephrol (2010) 1.13
Brain tumor tandem targeting using a combination of monoclonal antibodies attached to biopoly(beta-L-malic acid). J Control Release (2007) 1.13
Adenosine 5'-triphosphate-sensitive potassium channel-mediated blood-brain tumor barrier permeability increase in a rat brain tumor model. Cancer Res (2003) 1.12
Whole brain radiation therapy (WBRT) alone versus WBRT and radiosurgery for the treatment of brain metastases. Cochrane Database Syst Rev (2012) 1.12
Overexpression of beta1-chain-containing laminins in capillary basement membranes of human breast cancer and its metastases. Breast Cancer Res (2005) 1.12
Hedgehog signaling regulates brain tumor-initiating cell proliferation and portends shorter survival for patients with PTEN-coexpressing glioblastomas. Stem Cells (2008) 1.11
Development of an intracranial ependymoma at the site of a pre-existing cavernous malformation. Surg Neurol (2003) 1.10
Thymic CD8+ T cell production strongly influences tumor antigen recognition and age-dependent glioma mortality. J Immunol (2003) 1.10
Identification of prolyl carboxypeptidase as an alternative enzyme for processing of renal angiotensin II using mass spectrometry. Am J Physiol Cell Physiol (2013) 1.10
Cytotoxic T cell targeting of TRP-2 sensitizes human malignant glioma to chemotherapy. Oncogene (2005) 1.08
Angiotensin-converting enzyme C-terminal catalytic domain is the main site of angiotensin I cleavage in vivo. Hypertension (2007) 1.08
Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma. Clin Cancer Res (2007) 1.07
Antisense inhibition of laminin-8 expression reduces invasion of human gliomas in vitro. Mol Cancer Ther (2003) 1.06
Alzheimer's disease in the retina: imaging retinal aβ plaques for early diagnosis and therapy assessment. Neurodegener Dis (2012) 1.06
Mice lacking endothelial ACE: normal blood pressure with elevated angiotensin II. Hypertension (2003) 1.05
Janus kinase 2 determinants for growth hormone receptor association, surface assembly, and signaling. Mol Endocrinol (2003) 1.05
The carboxypeptidase ACE shapes the MHC class I peptide repertoire. Nat Immunol (2011) 1.04
Poly(malic acid) nanoconjugates containing various antibodies and oligonucleotides for multitargeting drug delivery. Nanomedicine (Lond) (2008) 1.04
Six truisms concerning ACE and the renin-angiotensin system educed from the genetic analysis of mice. Circ Res (2005) 1.04
Connective tissue growth factor associated with oncogenic activities and drug resistance in glioblastoma multiforme. Int J Cancer (2010) 1.04
Ligands for PPARgamma and RAR cause induction of growth inhibition and apoptosis in human glioblastomas. J Neurooncol (2003) 1.04
Intraoperative delineation of primary brain tumors using time-resolved fluorescence spectroscopy. J Biomed Opt (2010) 1.04
Regulation of blood-brain tumor barrier permeability by calcium-activated potassium channels. J Pharmacol Exp Ther (2002) 1.03
Cellular delivery of doxorubicin via pH-controlled hydrazone linkage using multifunctional nano vehicle based on poly(β-l-malic acid). Int J Mol Sci (2012) 1.02
Attenuation of AD-like neuropathology by harnessing peripheral immune cells: local elevation of IL-10 and MMP-9. J Neurochem (2009) 1.02
Cucurbitacin B markedly inhibits growth and rapidly affects the cytoskeleton in glioblastoma multiforme. Int J Cancer (2008) 1.00
Abnormal changes in NKT cells, the IGF-1 axis, and liver pathology in an animal model of ALS. PLoS One (2011) 1.00
AIM-2: a novel tumor antigen is expressed and presented by human glioma cells. J Immunother (2004) 1.00
Angiotensin-converting enzyme N-terminal inactivation alleviates bleomycin-induced lung injury. Am J Pathol (2010) 0.99